Abeona Therapeutics Inc. (ABEO): Price and Financial Metrics
ABEO Price/Volume Stats
| Current price | $4.25 | 52-week high | $6.13 |
| Prev. close | $4.29 | 52-week low | $2.19 |
| Day low | $3.79 | Volume | 623,000 |
| Day high | $4.38 | Avg. volume | 172,024 |
| 50-day MA | $3.17 | Dividend yield | N/A |
| 200-day MA | $3.25 | Market Cap | 79.81M |
ABEO Stock Price Chart Interactive Chart >
ABEO POWR Grades
- Sentiment is the dimension where ABEO ranks best; there it ranks ahead of 84.28% of US stocks.
- The strongest trend for ABEO is in Sentiment, which has been heading up over the past 179 days.
- ABEO ranks lowest in Stability; there it ranks in the 6th percentile.
ABEO Stock Summary
- ABEO's price/sales ratio is 56.62; that's higher than the P/S ratio of 96.6% of US stocks.
- Revenue growth over the past 12 months for ABEONA THERAPEUTICS INC comes in at -68.08%, a number that bests only 3.27% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ABEO comes in at -77.65% -- higher than that of only 7.39% of stocks in our set.
- Stocks that are quantitatively similar to ABEO, based on their financial statements, market capitalization, and price volatility, are BGRY, ONTX, IMGN, SRZN, and PTN.
- ABEO's SEC filings can be seen here. And to visit ABEONA THERAPEUTICS INC's official web site, go to www.abeonatherapeutics.com.
ABEO Valuation Summary
- In comparison to the median Healthcare stock, ABEO's EV/EBIT ratio is 119.17% lower, now standing at -2.3.
- Over the past 243 months, ABEO's EV/EBIT ratio has gone up 2.5.
Below are key valuation metrics over time for ABEO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABEO | 2023-05-23 | 55.5 | 3.2 | -1.9 | -2.3 |
| ABEO | 2023-05-22 | 56.9 | 3.2 | -1.9 | -2.3 |
| ABEO | 2023-05-19 | 54.5 | 3.1 | -1.8 | -2.2 |
| ABEO | 2023-05-18 | 52.5 | 3.0 | -1.8 | -2.1 |
| ABEO | 2023-05-17 | 52.1 | 3.0 | -1.7 | -2.1 |
| ABEO | 2023-05-16 | 53.3 | 3.0 | -1.8 | -2.2 |
ABEO Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at 15.26%.
- The 4 year price growth rate now stands at -60.81%.
- Its 2 year cash and equivalents growth rate is now at -34.71%.
The table below shows ABEO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 4.346 | -59.748 | -89.035 |
| 2022-06-30 | 4.346 | -63.291 | -86.595 |
| 2022-03-31 | 3.346 | -65.767 | -89.725 |
| 2021-12-31 | 3 | -65.665 | -84.936 |
| 2021-09-30 | 3 | -37.018 | -54.081 |
| 2021-06-30 | 10 | -37.386 | -54.274 |
ABEO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ABEO has a Quality Grade of C, ranking ahead of 61.27% of graded US stocks.
- ABEO's asset turnover comes in at 0.069 -- ranking 293rd of 682 Pharmaceutical Products stocks.
- MCRB, NVAX, and VXRT are the stocks whose asset turnover ratios are most correlated with ABEO.
The table below shows ABEO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.069 | 1 | -0.763 |
| 2021-03-31 | 0.065 | 1 | -0.616 |
| 2020-12-31 | 0.062 | 1 | -1.011 |
| 2020-09-30 | 0.039 | 1 | -1.361 |
| 2020-06-30 | 0.000 | NA | -2.242 |
| 2020-03-31 | 0.000 | NA | -3.902 |
ABEO Price Target
For more insight on analysts targets of ABEO, see our ABEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
Abeona Therapeutics Inc. (ABEO) Company Bio
Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company iwas founded n 1989 and is based in Dallas, Texas.
Latest ABEO News From Around the Web
Below are the latest news stories about ABEONA THERAPEUTICS INC that investors may wish to consider to help them evaluate ABEO as an investment opportunity.
Abeona Therapeutics to Present at the Jefferies Healthcare ConferenceCLEVELAND, June 01, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern time. The Company will also participate in one-on-one investor meetings at the conference. A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at https://investors.abeona |
ABEO: Additional Phase 3 VIITAL™ Data Presented at ISID MeetingBy David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Additional Data from VIITAL™ Trial Presented at ISID On May 24, 2023, Abeona Therapeutics Inc. (NASDAQ:ABEO) held a conference call to discuss additional data from the Phase 3 VIITAL study evaluating EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The data was recently presented at the inaugural |
Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference CallQ1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call |
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023CLEVELAND, May 22, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has changed the date of its previously announced First Quarter 2023 Portfolio Update conference call and webcast to Wednesday, May 24, 2023, at 8:30 a.m. ET. The call was previously scheduled for Tuesday, May 23, 2023, at 8:30 a.m. ET. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 885338 five minutes prior to the start of the call. A live |
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophyCLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking pl |
ABEO Price Returns
| 1-mo | 43.10% |
| 3-mo | 57.99% |
| 6-mo | 37.10% |
| 1-year | 0.06% |
| 3-year | -93.88% |
| 5-year | -98.93% |
| YTD | 37.99% |
| 2022 | -63.44% |
| 2021 | -78.54% |
| 2020 | -51.99% |
| 2019 | -54.20% |
| 2018 | -54.95% |
Continue Researching ABEO
Want to see what other sources are saying about Abeona Therapeutics Inc's financials and stock price? Try the links below:Abeona Therapeutics Inc (ABEO) Stock Price | Nasdaq
Abeona Therapeutics Inc (ABEO) Stock Quote, History and News - Yahoo Finance
Abeona Therapeutics Inc (ABEO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...